Literature DB >> 17873971

Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression.

Rui Wang1, Ke Dong, Fang Lin, Xi Wang, Ping Gao, San-Hua Wei, Shi-Yin Cheng, Hui-Zhong Zhang.   

Abstract

Stathmin (Oncoprotein18), a signal transduction regulatory factor, plays an important role in cell division and malignant tumor development. Stathmin is a ubiquitous intracellular phosphoprotein that is overexpressed in a variety of human malignancies, including osteosarcoma. To investigate the potential use of stathmin as a therapeutic target for human osteosarcomas, we employed RNA interference [small interfering RNA (siRNA)] to reduce stathmin expression in human osteosarcoma cell lines and analyzed their phenotypic changes. Results showed that the downregulation of stathmin expression in human osteosarcoma cells significantly inhibited cell proliferation in vitro and tumorigenicity in vivo. The specific downregulation induced cell arrest in the G(2)/M phase of cell cycle and eventually apoptotic cell death. Taxanes are a group of effective chemotherapeutic agents whose activity is mediated through stabilization of the microtubules of the mitotic spindle. In the present study, we also observed a synergistic enhancement of the cytotoxicity effect by combination use of taxanes and RNA interference-mediated stathmin downregulation. All these experimental data indicate that stathmin downregulation can lead to potent antitumor activity and chemosensitizing activity to taxanes in human osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873971      PMCID: PMC1976861          DOI: 10.2119/2007-00046.Wang

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  36 in total

1.  A protein sensor for siRNA asymmetry.

Authors:  Yukihide Tomari; Christian Matranga; Benjamin Haley; Natalia Martinez; Phillip D Zamore
Journal:  Science       Date:  2004-11-19       Impact factor: 47.728

Review 2.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.

Authors:  E K Rowinsky
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

3.  Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.

Authors:  Sucharita J Mistry; George F Atweh
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

4.  Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells.

Authors:  Hui-Zhong Zhang; Yan Wang; Ping Gao; Fang Lin; Li Liu; Bing Yu; Ji-Hong Ren; Hui Zhao; Rui Wang
Journal:  Cancer Biol Ther       Date:  2006-11-13       Impact factor: 4.742

Review 5.  Oncoprotein signalling and mitosis.

Authors:  A D Laird; D Shalloway
Journal:  Cell Signal       Date:  1997 May-Jun       Impact factor: 4.315

6.  Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase.

Authors:  X N Luo; B Mookerjee; A Ferrari; S Mistry; G F Atweh
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

7.  Taxol suppresses dynamics of individual microtubules in living human tumor cells.

Authors:  A M Yvon; P Wadsworth; M A Jordan
Journal:  Mol Biol Cell       Date:  1999-04       Impact factor: 4.138

8.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.

Authors:  Gaetano Bacci; Alessandra Longhi; Michela Versari; Mario Mercuri; Antonio Briccoli; Piero Picci
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

9.  Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules.

Authors:  L D Belmont; T J Mitchison
Journal:  Cell       Date:  1996-02-23       Impact factor: 41.582

10.  Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo.

Authors:  B Howell; H Deacon; L Cassimeris
Journal:  J Cell Sci       Date:  1999-11       Impact factor: 5.285

View more
  22 in total

1.  The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.

Authors:  Nancy S Vetter; E A Kolb; Christopher C Mills; Valerie B Sampson
Journal:  Mol Cancer Res       Date:  2017-03-08       Impact factor: 5.852

2.  Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production.

Authors:  Camelia Iancu-Rubin; David Gajzer; Joseph Tripodi; Vesna Najfeld; Ronald E Gordon; Ronald Hoffman; George F Atweh
Journal:  Blood       Date:  2011-03-01       Impact factor: 22.113

3.  Stathmin is a potential molecular marker and target for the treatment of gastric cancer.

Authors:  Xiaolin Liu; Hairong Liu; Jing Liang; Beibei Yin; Junjuan Xiao; Junwei Li; Dongfeng Feng; Yan Li
Journal:  Int J Clin Exp Med       Date:  2015-04-15

4.  Identification of ING4 (inhibitor of growth 4) as a modulator of docetaxel sensitivity in human lung adenocarcinoma.

Authors:  Rui Wang; Jiayuan Huang; Bing Feng; Wei De; Longbang Chen
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

5.  MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression.

Authors:  Yuwen Song; Luyan Mu; Xuezhe Han; Qingla Li; Baijing Dong; Hulun Li; Xiaoqian Liu
Journal:  J Neurooncol       Date:  2013-09-17       Impact factor: 4.130

6.  Gene expression profiles in mouse embryo fibroblasts lacking stathmin, a microtubule regulatory protein, reveal changes in the expression of genes contributing to cell motility.

Authors:  Danielle N Ringhoff; Lynne Cassimeris
Journal:  BMC Genomics       Date:  2009-07-30       Impact factor: 3.969

7.  Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: in vitro and in vivo.

Authors:  Xiang Hu; Yang Liu; Chunxia Qin; Zhenyu Pan; Jun Luo; Aixi Yu; Zhen Cheng
Journal:  Cancer Lett       Date:  2013-12-22       Impact factor: 8.679

8.  Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients.

Authors:  Wang Xi; Wang Rui; Lin Fang; Dong Ke; Gao Ping; Zhang Hui-Zhong
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-26       Impact factor: 4.553

9.  A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.

Authors:  Yong Wu; Min Tang; Yuan Wu; Xinxian Weng; Lifang Yang; Wen Xu; Wie Yi; Jinghe Gao; Ann M Bode; Zigang Dong; Ya Cao
Journal:  Cell Oncol (Dordr)       Date:  2013-12-05       Impact factor: 6.730

10.  Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells.

Authors:  T-Y Jeon; M-E Han; Y-W Lee; Y-S Lee; G-H Kim; G-A Song; G-Y Hur; J-Y Kim; H-J Kim; S Yoon; S-Y Baek; B-S Kim; J-B Kim; S-O Oh
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.